Ventracor Limited

October 11, 2005

Ventracor Limited (ASX: VCR) announced today it had completed the field exchange of all controllers of the VentrAssistTM left ventricular assist system (LVAS).

Ventracor Chief Executive Officer Colin Sutton PhD said: "All patients in the US, Europe and Australia have had their controllers exchanged without incident.

"Recruitment in our clinical trial program has been progressing well with three US patients implanted to-date, bringing the total number, including the completed Pilot Trial, of VentrAssist implants to over 30 globally," Dr Sutton said.

As noted previously, Ventracor is currently undertaking additional screening and quality control to ensure the anomaly identified in the cable supplied to it is eliminated.

Dr Sutton said the field exchange and additional screening will delay Ventracor's global clinical trial program, including the CE Mark and US Feasibility trials which were targeted for completion by the end of the 2005 calendar year.

"However, we expect both milestones will be achieved within the first quarter of the 2006 calendar year.

"We do not expect this to adversely impact our progress and the achievement of key milestones in the longer term.

"The costs incurred in the field exchange program are not material in the context of our overall financial commitment to our global clinical trial program.

"Throughout this process, we will ensure the market is kept progressively informed on a timely basis," Dr Sutton said.
-end-
About Ventracor
Ventracor is a global medical device company that has developed an implantable blood pump, the VentrAssistTM left ventricular assist system (LVAS) for patients in cardiac failure. The company hopes to bring the VentrAssistTM to the global market in record time, and expects to obtain a significant share of the huge potential market.

For further information, please contact:

Andrew Geddes
Manager, Investor Relations
Ventracor Limited
T: + 61 2 9406 3086
-end-


Research Australia

Related Additional Screening Articles from Brightsurf:

Study provides additional support for use of new class of diabetes drugs
A new study led by a cardiologist from Brigham and Women's Hospital has assessed the cardiovascular and renal outcomes for ertugliflozin, an SGLT2 inhibitor prescribed for patients with type 2 diabetes to help them control blood sugar levels.

0.5°C of additional warming has a huge effect on global aridity
In a simulation study, UTokyo researchers showed that limiting global warming to 1.5°C rather than 2°C will mitigate aridification in some regions of the world including the Mediterranean, western Europe, and southern Africa.

COVID-19 patients with sleep apnoea could be at additional risk
People who have been diagnosed with obstructive sleep apnoea could be at increased risk of adverse outcomes from COVID-19 according to a new study from the University of Warwick.

Additional data on blood thinner efficacy for COVID-19 and insight on best possible regimens
Mount Sinai study is the basis of a new international clinical trial.

Mailed colorectal cancer screening kits may save costs while increasing screening rates
New research indicates that mailing colorectal cancer screening kits to Medicaid enrollees is a cost-effective way to boost screening rates.

Doctors motivated by both health, malpractice concerns when ordering additional tests
A UCLA-led study has found that dermatopathologists, who specialize in diagnosing skin diseases at the microscopic level, are motivated both by patient safety concerns and by malpractice fears -- often simultaneously -- when ordering multiple tests and obtaining second opinions, with a higher proportion of these doctors reporting patient safety as a concern.

HPV vaccine hesitancy in Japan could result in 5,000 additional death
The precipitous drop in HPV vaccination rates after suspension of proactive recommendations by the government in 2013 could result in an additional 25,000 cervical cancer cases and more than 5,000 additional deaths among females born between 1994 to 2007 in Japan.

Study shows risks for additional procedures after bariatric surgery
Which of the two most common bariatric surgeries -- gastric sleeve or gastric bypass -- has the highest subsequent risk of additional operations or procedures?

An additional component can triple vaccine efficiency, and scientists explained how
A team of Russian scientists carried out a study on the cell immunity level and found out how an adjuvant called azoximer bromide increases the immunogenicity of the anti-flu vaccine.

Additional medications to treat children with JIA are urgently needed
According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, there is a profound ongoing need for additional medications to control the signs and symptoms of juvenile idiopathic arthritis (JIA), despite the availability of several approved biologic disease-modifying antirheumatic drugs (biologics).

Read More: Additional Screening News and Additional Screening Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.